Entero Healthcare Solutions Limited has informed the Exchange regarding Board meeting held on September 29, 2025.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Entero Healthcare's board approved two transactions on September 29, 2025. First, the company will sell its entire 100% stake in wholly-owned subsidiary Suprabhat Pharmaceutical for up to INR 37 lakh to the erstwhile promoters of Suprabhat; this unit contributed only 0.39% of consolidated income (INR 198.76 million) and 0.01% of net worth, making it a minor divestiture. Second, the company will acquire a 60% stake in Ace Cardiopathy Solutions, a Delhi-based wholesale distributor of medical devices, for a cash consideration ranging between INR 59.30 crore and INR 77.10 crore, subject to due diligence and definitive agreements. Ace Cardiopathy reported turnover of INR 154.8 crore in FY25 (unaudited), INR 176.2 crore in FY24, and INR 153 crore in FY23. The acquisition is expected to close by January 31, 2026, and is not a related-party transaction.
The Ace Cardiopathy acquisition, at up to INR 77.10 crore for 60%, implies a valuation that meaningfully expands Entero's medical device distribution footprint given Ace's INR 150+ crore revenue base. The Suprabhat sale is financially negligible. Net effect is mildly positive — strategic consolidation in core business, though investors should watch for due diligence outcomes and final pricing.